Leask, A., Xu, S. W., Renzoni, E. A., Bou-Gharios, G., du Bois, R. M., Abraham, D. J., & Black, C. M. (2005). Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma. 52(9), S164–S165.

Leask, A., et al. Bosentan Alleviates the pro-Fibrotic Phenotype of Lung Scleroderma Fibroblasts: Implications for Treatment of Scleroderma. no. 9, 2005, pp. S164–S165.

Leask, A, SW Xu, EA Renzoni, G Bou-Gharios, RM du Bois, DJ Abraham, and CM Black. 2005. “Bosentan Alleviates the pro-Fibrotic Phenotype of Lung Scleroderma Fibroblasts: Implications for Treatment of Scleroderma.” In , 52:S164–S165.